Is this a death knell for anti-interleukin-5 therapy in asthma?

被引：0
|
作者：
Phillip Lieberman
机构：
来源：
Current Allergy and Asthma Reports | 2009年 / 9卷 / 1期
关键词：
Asthma; Respir Crit; Beclomethasone; Exacerbation Rate; Sputum Eosinophil;
D O I：
10.1007/s11882-009-0006-5
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] The interest of anti-interleukin-5 in the treatment of the hypereosinophilic syndrome and allergic diseases
    Pouwels-Fry, S
    Wallaert, B
    REVUE FRANCAISE D ALLERGOLOGIE ET D IMMUNOLOGIE CLINIQUE, 2006, 46 (03): : 257 - 260
  • [42] Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis
    Plotz, S
    Simon, H
    Darsow, U
    Simon, D
    Vassina, E
    Yousefi, S
    Hein, R
    Smith, T
    Behrendt, H
    Ring, J
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (24): : 2334 - 2339
  • [43] A Systematic Literature Review of Real-World Outcomes Following Anti-Interleukin-5 and Anti-Interleukin-5 Receptor Alpha Treatment for Hypereosinophilic Syndrome: Case Reports and Cohort Studies
    Jain, Priya
    Rowell, Jennifer
    Edmonds, Chris
    Stokes, Michael
    Ding, Ning
    Chen, Stephanie Yanjing
    BLOOD, 2024, 144 : 5090 - 5091
  • [44] Anti-interleukin-5 and multiple autoantibodies are associated with human atherosclerotic diseases and serum interleukin-5 levels
    Ishigami, Tomoaki
    Abe, Kaito
    Aoki, Ichiro
    Minegishi, Shintaro
    Ryo, Akihide
    Matsunaga, Satoko
    Matsuoka, Kazuhiro
    Takeda, Hiroyuki
    Sawasaki, Tatsuya
    Umemura, Satoshi
    Endo, Yaeta
    FASEB JOURNAL, 2013, 27 (09): : 3437 - 3445
  • [45] Angiolymphoid hyperplasia with eosinophilia treated with anti-interleukin-5 antibody (mepolizumab)
    Braun-Falco, M
    Fischer, S
    Plötz, SG
    Ring, J
    BRITISH JOURNAL OF DERMATOLOGY, 2004, 151 (05) : 1103 - 1104
  • [46] Evaluation of bronchial hyperreactivity and other functional parameters in severe asthma patients treated with anti-interleukin-5 monoclonal antibody (IL5)
    Bini, Francesco
    Grassi, Noemi
    Visca, Dina
    De Lauretis, Angelo
    SpaneNoello, Antonio
    Vaghi, Adriano
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [47] Anti-interleukin Therapy in Asthma
    Dunn, R. M.
    Wechsler, M. E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 (01) : 55 - 65
  • [48] Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy
    O'Reilly, Emily
    Casey, Deborah
    Ibrahim, Hisham
    McGrath, Alice
    McHugh, Tomas
    Vairamani, Punitha
    Murphy, Jill
    Plant, Barry
    Murphy, Desmond M.
    JOURNAL OF ASTHMA AND ALLERGY, 2022, 15 : 935 - 937
  • [49] Anti-interleukin-5 in the Management of Eosinophilic Asthma: A Review of Effectiveness, Safety, and Budgetary Impact From the Perspective of the Brazilian Health System
    de Freitas Nakata, Kelli Carneiro
    Marques, Luisa Daige
    de Oliveira, Helder Cassio
    Magalhaes, Graciane Catarina Batista
    de Oliveira, Ruberlei Godinho
    Botelho, Clovis
    VALUE IN HEALTH REGIONAL ISSUES, 2021, 26 : 169 - 181
  • [50] Factors Affecting the Ability to Discontinue Oral Corticosteroid Use in Patients with EGPA Treated with Anti-Interleukin-5 Therapy
    Matsuno, Osamu
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2024, 185 (02) : 116 - 123
12345